Clinical Trial Search

Primary: Objective Response Rate by Independent Review Group — 86 percent of participants

Primary: Confirmed Response, Defined as Objective Complete Remission or Partial Remission for a Duration of at Least 2 Months — 27 participants

Primary: Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18 — 0; 5; 0; 4 subjects

Primary: Percentage of Participants Who Require Anticoagulation and/or Have Clinical Signs of Catheter Related Thrombosis — 10.5; 14.3; 10.0 Percentage of participants

Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants

Primary: Change in the Weekly Urticaria Activity Score (UAS7) From Baseline to the End of the Study (Week 24) — -17.8; -5.8 Units on a scale

Primary: Median Progression-free Survival (PFS) — 12.8 Months

Primary: Progression-free Survival — 2.2; 2.6 months — p=0.6873

Primary: Number of Participants (Par.) With Complete Remission (CR), Measured From Start of Treatment Until 3 Months After Last Infusion — 10; 15 participants

Primary: Progression-free Survival in the Subgroup of Participants With βIII-tubulin Positive Tumors — 4.27; 4.27 Months — p=0.5735

Primary: N-back Task - Reaction Time — 786; 684 msec — p=0.16

Primary: Percent of Participants With Primary Safety Endpoint — 0; 0; 0; 0 percentage of participants

Primary: Progression Free Survival (PFS) — 2.9; 3.2 months — p=0.0047

Primary: Proportion of Participants With Virologic Failure After Initiating RAL Plus DRV/RTV at or Prior to Week 24 — 0.16 Proportion of participants

Primary: Number of Participants With Either an Infection or a Grade III or IV Adverse Event (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE]…